ClinicalTrials.gg
Active, not recruitingNCT07530419SAVID-SLDUpdated Oct 13, 2026

Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)

An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver and Liver Fibrosis, sponsored by Seoul National University Hospital. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Seoul National University Hospital · Observational

How we know

Updated Oct 13, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
95
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Fatty Liver with a site in Korea, Republic of — 7 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Korea, Republic of.

Started
2026
the only one that year
Observational
7 of 23
1 open now
Primary completion
2026-10
later than 5 of 11 live
Registered
23rd of 23
by date
Lead sponsor
7 of 23
Seoul National University Hospital

Among the 23 studies in Fatty Liver with a site in Korea, Republic of, this one is the only one that started in 2026, is one of 7 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 23rd registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

7 of the 23 studies in Fatty Liver with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fatty Liver with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Steatotic liver disease (SLD) is one of the most common chronic liver diseases worldwide. Distinguishing simple steatosis from metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is clinically important, but liver biopsy - the current standard - is invasive. Recent ultrasound technology allows noninvasive measurement of tissue viscoelasticity, which has been linked to liver inflammation. Samsung Medison's R20 system (S-Viscosity) and Canon Aplio i800 (Dispersion Slope Imaging) both provide vendor-specific viscoelasticity parameters derived from shear-wave dispersion analysis, but their relationship and agreement have not been compared in SLD patients.

This prospective single-center observational study will enroll approximately 95-100 participants in three cohorts: (A) 15-20 living-donor candidates as a healthy reference, (B+C) approximately 80 adults with sonographically suspected or confirmed SLD recruited consecutively. SLD participants will be classified post-hoc into low-MASH-risk (Cohort B) and at-risk MASH (Cohort C) subgroups using a multi-parametric stratification combining liver stiffness (LSM), DeepUSFF (deep-learning-based ultrasound fat fraction), and serum AST. All participants will undergo same-day ultrasound examination with both Samsung HERA W12 and Canon Aplio i800. The primary objective is to evaluate the correlation and agreement between Samsung S-Viscosity and Canon Dispersion Slope. Secondary objectives include deriving a normal reference range from the healthy cohort, comparing viscoelasticity parameters across cohorts, and exploring a Modified US-FAST score.

Read the detailed description

Background: Two-dimensional shear wave elastography (2D SWE) is widely used to quantify liver stiffness for fibrosis assessment, but stiffness can be confounded by inflammation, congestion, and other factors. Frequency-dependent shear-wave dispersion analysis yields viscosity-related parameters that may reflect tissue inflammation. Canon's Dispersion Slope Imaging (DS, [m/s]/kHz) has been validated against histology in the multicenter iLEAD study (Sugimoto et al., Radiology 2024) and shown to correlate with lobular inflammation in MASLD. Samsung Medison has recently introduced S-Viscosity within the S-Shearwave platform of the HERA W12 R30 system, providing dispersion-derived viscosity parameters from a single SWE acquisition; however, head-to-head comparison with Canon DS in SLD patients has not been reported.

Hypothesis: Samsung S-Viscosity and Canon Dispersion Slope, both derived from frequency-dependent shear-wave analysis, will demonstrate moderate-to-strong correlation and clinically acceptable inter-vendor agreement in patients with steatotic liver disease.

Study Design: Single-center, prospective, non-interventional observational study. Adult participants (≥18 years) will be enrolled into three cohorts: Cohort A (Healthy reference, n=15-20): living-donor candidates with confirmed steatosis \<5%, normal LFTs, and exclusion of chronic liver disease, recruited during routine donor evaluation. Cohort B+C (SLD, n≈80): adults with sonographically suspected or confirmed hepatic steatosis scheduled for clinical abdominal ultrasound, recruited consecutively. Post-hoc stratification of SLD participants uses LSM (2D S-SWE), DeepUSFF, and serum AST with institutionally-validated cutoffs (LSM 6.82 kPa for ≥F2 fibrosis; DeepUSFF asymmetric cutoffs of 7.86% for \<S1 rule-out and 15.05% for ≥S2 rule-in; AST 40 U/L institutional ULN) to define Low MASH risk (Cohort B), At-risk MASH (Cohort C), and an Indeterminate zone.

Procedures: All participants undergo same-day ultrasound examinations on both Samsung HERA W12 (CA 1-7S probe) and Canon Aplio i800 (i8C1 probe) in randomized order, with operators blinded to LFT results at the time of scanning. From the right hepatic lobe via right intercostal approach after a minimum 4-hour fast: Samsung acquisitions include 2D S-Viscosity, 2D S-SWE, TAI, and DeepUSFF (5 measurements per parameter, 2 sessions); Canon acquisitions include Dispersion Slope Imaging and 2D SWE (5 measurements). Median values are used as representative.

Statistical Analysis: Primary endpoints - Pearson or Spearman correlation between Samsung S-Viscosity and Canon Dispersion Slope (with 95% CI), and Bland-Altman analysis of inter-vendor agreement (mean bias and 95% limits of agreement). Sample size of approximately 80 SLD participants provides adequate precision for both correlation (r=0.4 to 0.6) and Bland-Altman limits-of-agreement estimation (±0.5 SD precision). Secondary endpoints include 95% reference interval derivation from Cohort A (n≥15 for nonparametric estimation), inter-cohort comparisons, Modified US-FAST score exploration, reproducibility (ICC and CV%), and technical success rate.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Fatty Liver
  • Liver Fibrosis

Keywords

  • Shear wave elastography
  • Viscoelasticity
  • Dispersion slope
  • Liver stiffness
  • Quantitative ultrasound
  • MASLD
  • MASH
  • S-Viscosity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older recruited from Seoul National University Hospital, including (1) living-donor candidates undergoing donor evaluation as a healthy reference cohort, and (2) outpatients with sonographically suspected or confirmed hepatic steatosis scheduled for clinical abdominal ultrasound.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • [Cohort A - Healthy reference]

    • Adults ≥18 years old
    • Currently undergoing living-donor evaluation at SNUH
    • Donor evaluation confirms (a) hepatic steatosis \<5% by imaging or , (b) normal /ALT, and (c) absence of chronic liver disease (, , , cholestatic, etc.)
    • Provided written [Cohort B + C - Steatotic liver disease]
    • Adults ≥18 years old
    • Sonographically suspected or confirmed hepatic steatosis on B-mode ultrasound, scheduled for clinical abdominal ultrasound
    • Serum AST/ALT results available within 6 weeks of ultrasound, or scheduled
    • Provided written informed consent

Exclusion criteria

Exclusion Criteria:

    • Significant alcohol intake within the past 2 years (>30-60 g/day for males, >20-50 g/day for females)

      • Diagnosed or strongly suspected chronic liver disease (active /, liver disease, cholestatic liver disease, Wilson's disease, hemochromatosis, etc.)
      • Suspected hepatic failure or decompensated cirrhosis (albumin \<3.2 g/dL, >1.3, direct >1.3 mg/dL)
      • Ascites, history of variceal bleeding, or acute biliary obstruction rendering stable measurements unfeasible
      • History of liver or treatment for liver malignancy
      • History of liver surgery
      • Pregnancy or lactation
      • Inadequate ultrasound image quality due to obesity, bowel gas, or patient inability to cooperate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
95 participants (estimated)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Cohort A: Healthy Reference (Living-donor candidates)

    Adult living-donor candidates undergoing donor evaluation at SNUH. Confirmed hepatic steatosis \<5%, normal AST/ALT, and absence of chronic liver disease. Participation does not affect donor candidacy decisions.

    Device: Samsung Medison HERA W12 (R30) with S-Shearwave platform · Device: Canon Aplio i800 with Dispersion Slope Imaging

  • Cohort B: Low MASH Risk MASLD (Rule-out)

    Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as low MASH risk by satisfying ALL three criteria: LSM \<6.82 kPa AND DeepUSFF \<7.86% (\<S1) AND AST ≤40 U/L (institutional ULN).

    Device: Samsung Medison HERA W12 (R30) with S-Shearwave platform · Device: Canon Aplio i800 with Dispersion Slope Imaging

  • Cohort C: At-Risk MASH MASLD (Rule-in)

    Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as at-risk MASH by satisfying mandatory LSM ≥6.82 kPa (suggestive of ≥F2 significant fibrosis) AND at least one of: DeepUSFF ≥15.05% (≥S2) OR AST \>40 U/L. Participants meeting neither Cohort B nor Cohort C definitions are classified as 'Indeterminate' and analyzed as an exploratory subgroup.

    Device: Samsung Medison HERA W12 (R30) with S-Shearwave platform · Device: Canon Aplio i800 with Dispersion Slope Imaging

  • Cohort D: Indeterminate Zone (Exploratory subgroup)

    Adults with sonographically suspected or confirmed hepatic steatosis who do not meet the full criteria for either Cohort B (Low MASH risk) or Cohort C (At-risk MASH). This cohort primarily includes participants with DeepUSFF values in the S1 range (7.86% to \<15.05%), or those meeting only a subset of the Cohort B/C criteria. Cohort D is analyzed as a pre-specified exploratory subgroup and is not included in the primary stratified comparison between Cohort B and Cohort C. Descriptive statistics are reported separately.

    Device: Samsung Medison HERA W12 (R30) with S-Shearwave platform · Device: Canon Aplio i800 with Dispersion Slope Imaging

Interventions

  • DeviceSamsung Medison HERA W12 (R30) with S-Shearwave platform

    Two-dimensional shear-wave elastography acquisition with the Samsung HERA W12 R30 system using the CA 1-7S convex probe. Five valid measurements per parameter are obtained from the right hepatic lobe via right intercostal approach, repeated in 2 sessions. Output parameters include S-Viscosity (dispersion-derived viscosity index), 2D S-SWE (liver stiffness in kPa), TAI (tissue attenuation imaging), and DeepUSFF (deep-learning-based ultrasound fat fraction in %).

  • DeviceCanon Aplio i800 with Dispersion Slope Imaging

    Two-dimensional shear-wave elastography and Dispersion Slope Imaging acquisition with the Canon Aplio i800 system using the i8C1 convex probe. Five valid measurements are obtained from the right hepatic lobe via right intercostal approach. Output parameters include 2D SWE (liver stiffness in kPa) and Dispersion Slope (in \[m/s\]/kHz, viscosity-related).

06

What researchers measure

Primary outcomes

  1. Correlation between Samsung S-Viscosity and Canon Dispersion Slope

    Pearson or Spearman correlation coefficient (with 95% CI) between Samsung S-Viscosity and Canon Dispersion Slope, calculated from the median of 5 valid measurements per device per participant.

    Time frame: At the time of single study visit (Day 0)

  2. Inter-vendor agreement (Bland-Altman analysis)

    Mean bias and 95% limits of agreement between Samsung S-Viscosity and Canon Dispersion Slope calculated by Bland-Altman analysis. As the two parameters use different units, agreement will also be assessed after z-score transformation

    Time frame: At the time of single study visit (Day 0)

Secondary outcomes

  1. Normal reference range of viscoelasticity parameters

    95% reference interval (2.5-97.5 percentile) of Samsung S-Viscosity and Canon Dispersion Slope estimated nonparametrically from Cohort A (healthy reference cohort).

    Time frame: At the time of single study visit (Day 0)

  2. Inter-cohort comparison of viscoelasticity parameters

    Difference in Samsung S-Viscosity and Canon Dispersion Slope between Cohort B (Low MASH risk) and Cohort C (At-risk MASH), tested by t-test or Mann-Whitney U.

    Time frame: At the time of single study visit (Day 0)

  3. Modified US-FAST score performance (exploratory)

    AUROC of a Modified US-FAST score - calculated by substituting Samsung 2D S-SWE LSM and DeepUSFF into the LSM and CAP positions of the original FAST score formula (Newsome et al., Lancet Gastroenterol Hepatol 2020) - for identifying Cohort C participants. Correlation with Canon Dispersion Slope is also assessed.

    Time frame: At the time of single study visit (Day 0)

  4. Reproducibility of viscoelasticity measurements

    Intraclass correlation coefficient (ICC, 2-way random effects) and coefficient of variation (CV%) of repeated viscoelasticity measurements across two acquisition sessions per device.

    Time frame: At the time of single study visit (Day 0)

  5. Technical success rate

    Proportion of participants in whom valid viscoelasticity measurements were successfully obtained on both devices (Samsung HERA W12 and Canon Aplio i800).

    Time frame: At the time of single study visit (Day 0)

07

Study locations

1 site
08

References and documents

Publications

  • Sugimoto K, et al. US Markers and Necroinflammation, Steatosis, and Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease: The iLEAD Study. Radiology. 2024;312(2):e233377. Newsome PN, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-373. Barr RG, et al. Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology. 2020;296(2):263-274. WFUMB Guidelines/Guidance on Liver Multiparametric Ultrasound. Ultrasound Med Biol. 2024;50(8):1088-1098.
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.

Of 88 non-industry observational studies under Fatty Liver, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 68. This study's planned 5 months is below that.

Counting every sponsor, half of 97 studies reached it within 33 months; a quarter within 20 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Oct 2026 and completion Feb 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Oct 7, 2026was Dec 2026
CompletionEst.
Dec 30, 2027was Feb 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 13, 2026
Start date
Apr 10, 2026→Apr 24, 2026 (actual)
Oct 13, 2026
Primary completion
Dec 30, 2026→Oct 7, 2026
Oct 13, 2026
Study completion
Feb 28, 2027→Dec 30, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Active, not recruiting
    Start date Apr 10, 2026→Apr 24, 2026 (now actual)
    Primary completion Dec 30, 2026→Oct 7, 2026
    Study completion Feb 28, 2027→Dec 30, 2027
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07530419
Responsible party
Jeong Min Lee (Professor, Seoul National University Hospital) — Principal investigator
First posted
Apr 15, 2026
Start date
Apr 24, 2026
Primary completion
Oct 7, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion